
 1.  Short title This Act may be cited as the  Better Empowerment Now to Enhance Framework and Improve Treatments Act of 2021  or the  BENEFIT Act of 2021 .
  2.  Strengthening the use of patient-experience data within benefit-risk framework Section 569C of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 360bbb–8c ) is amended—
 (1)  in subsection (a)(1)—   (A) in subparagraph (A), by striking  ; and  and inserting a semicolon;
 (B) in subparagraph (B), by striking the period and inserting  ; and ; and  (C)  by adding at the end the following: 

 (C)  as part of the risk-benefit assessment framework in the new drug approval process described in section 505(d), considering relevant patient-focused drug development data, such as data from patient preference studies (benefit-risk), patient reported outcome data, or patient experience data, developed by the sponsor of an application or another party.  ; and   (2) in subsection (b)(1), by inserting  , including a description of how such data and information were considered in the risk-benefit assessment described in section 505(d)  before the period.

